AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21333876 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Group A and Group B)
Number of subjects: 87
Study 19018783 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose pioglitazone (7.5 mg/day; 21/28 days)
Number of subjects: 38
Study 19018783 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose flutamide (62.5 mg/day; 21/28 days)
Number of subjects: 38
Study 19018783 — intervention group
Group type: COMPARATOR
Intervention: Metformin and oestro-progestagen (control treatment)
Number of subjects: 38
Study 17055728 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall anxiety manipulation (increased threat to postural control)
Number of subjects: 30
Study 14643577 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 to 10 mg)
Number of subjects: 58
Study 14643577 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (80 to 160 mg)
Number of subjects: 58
Study 11287711 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 1.0 mg/kg intravenously (without abciximab)
Number of subjects: 0
Study 11287711 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced dose enoxaparin 0.75 mg/kg in combination with standard-dose abciximab intravenously during PCI
Number of subjects: 0
Study 11287711 — intervention group
Group type: COMPARATOR
Intervention: Combination of low-dose, weight-adjusted unfractionated heparin and abciximab
Number of subjects: 0
Study 9505993 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of valspodar (200 mg as a 2-hour infusion)
Number of subjects: 24
Study 9505993 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of valspodar (400 mg as microemulsion soft gelatin capsules)
Number of subjects: 24
Study 9505993 — intervention group
Group type: COMPARATOR
Intervention: Comparison of intravenous and oral administration of valspodar
Number of subjects: 24
Study 7939618 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead in air (PbA) in the casting and pasting area: 92.01 micrograms/m3
Number of subjects: 20
Study 7939618 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead in air (PbA) in the assembly line area: 85.73 micrograms/m3
Number of subjects: 20
Study 7939618 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead in air (PbA) in the battery charging and sales area: 36.31 micrograms/m3
Number of subjects: 20
Study 7939618 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead in air (PbA) in the administration area: 4.2 micrograms/m3
Number of subjects: 20
Study 3304403 — intervention group
Group type: EXPERIMENTAL
Intervention: Women holding their full case notes
Number of subjects: 290
Study 3304403 — intervention group
Group type: COMPARATOR
Intervention: Women holding their co‐operation card
Number of subjects: 290
Study 31280343 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-meal whey protein (WP) intake
Number of subjects: 0
Study 31280343 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-meal whey protein (WP)
Number of subjects: 0
Study 31280343 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-meal casein
Number of subjects: 0
Study 31280343 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-meal gluten
Number of subjects: 0
Study 29504666 — intervention group
Group type: EXPERIMENTAL
Intervention: FamTechCare telehealth intervention providing individualized dementia-care strategies based on caregiver video recordings.
Number of subjects: 0
Study 29504666 — intervention group
Group type: COMPARATOR
Intervention: Weekly phone call feedback for control group caregivers.
Number of subjects: 0
Study 29504666 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost for FamTechCare intervention.
Number of subjects: 0
Study 26819195 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen
Number of subjects: 17
Study 26819195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 25704314 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy (LLLT)
Number of subjects: 46
Study 25704314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 23034644 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (R)
Number of subjects: 46
Study 23034644 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training (R + E)
Number of subjects: 46
Study 23034644 — intervention group
Group type: COMPARATOR
Intervention: Endurance training (E)
Number of subjects: 46
Study 23034644 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 46
Study 21569370 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational Stimulation for Elders as a Vehicle to resolve DSD (RESERVE-DSD)
Number of subjects: 256
Study 21569370 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 256
Study 19236277 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Number of subjects: 17622
Study 16449396 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based collaborative depression treatment (pharmacotherapy, problem-solving treatment, or both)
Number of subjects: 329
Study 16449396 — intervention group
Group type: COMPARATOR
Intervention: Usual primary care (routine medical services)
Number of subjects: 329
Study 12711467 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-guided cutting needle biopsy
Number of subjects: 50
Study 12711467 — intervention group
Group type: COMPARATOR
Intervention: Abrams' pleural biopsy (standard care)
Number of subjects: 50
Study 10718681 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release carbamazepine (CBZ-CR) 400 mg initially, then 400 mg BID for 1 month
Number of subjects: 16
Study 10718681 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) 300 mg/day for 3 months
Number of subjects: 16
Study 10718681 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP) 1800 mg/day for 3 months
Number of subjects: 16
Study 10718681 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 16
Study 9184262 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients (group B)
Number of subjects: 45
Study 9184262 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients (group D)
Number of subjects: 45
Study 1549830 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid oxygen
Number of subjects: 15
Study 1549830 — intervention group
Group type: COMPARATOR
Intervention: Gaseous oxygen
Number of subjects: 15
Study 3944270 — intervention group
Group type: EXPERIMENTAL
Intervention: TxB2 infusion at 0.1 ng/kg X min
Number of subjects: 4
Study 3944270 — intervention group
Group type: EXPERIMENTAL
Intervention: TxB2 infusion at 1.0 ng/kg X min
Number of subjects: 4
Study 3944270 — intervention group
Group type: EXPERIMENTAL
Intervention: TxB2 infusion at 5.0 ng/kg X min
Number of subjects: 4
Study 3944270 — intervention group
Group type: COMPARATOR
Intervention: Aspirin treatment at 325 mg/d
Number of subjects: 4
Study 3944270 — intervention group
Group type: COMPARATOR
Intervention: Control (vehicle alone)
Number of subjects: 4
Study 3944270 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall rate of entry of endogenous TxB2 into circulation
Number of subjects: 4
Study 3944270 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate of disappearance of immunoreactive TxB2
Number of subjects: 4
Study 3944270 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal estimate of plasma concentration of endogenous TxB2
Number of subjects: 4
Study 30354330 — intervention group
Group type: EXPERIMENTAL
Intervention: GIST (Genotype Informed Statin Therapy)
Number of subjects: 159
Study 30354330 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 159
Study 30354330 — intervention group
Group type: EXPERIMENTAL
Intervention: SLCO1B1 testing
Number of subjects: 159
Study 26630992 — intervention group
Group type: EXPERIMENTAL
Intervention: TFMPP (60 mg)
Number of subjects: 100
Study 26630992 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamphetamine (20 mg)
Number of subjects: 100
Study 26630992 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzylpiperazine (BZP) (200 mg)
Number of subjects: 100
Study 26630992 — intervention group
Group type: EXPERIMENTAL
Intervention: BZP + TFMPP (100/30 mg)
Number of subjects: 100
Study 26630992 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 100
Study 25518117 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint injection of Metoclopramide (5 mg + normal saline) into bilateral Zusanli (ST 36) and Weishu (BL 21)
Number of subjects: 46
Study 25518117 — intervention group
Group type: COMPARATOR
Intervention: Control group treated by injection of 10 mg of Metoclopramide into the deltoid muscle and gluteus maximus muscle
Number of subjects: 46
Study 22445775 — intervention group
Group type: EXPERIMENTAL
Intervention: Savory diet
Number of subjects: 39
Study 22445775 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweet diet
Number of subjects: 39
Study 22445775 — intervention group
Group type: COMPARATOR
Intervention: Savory diet and Sweet diet
Number of subjects: 39
Study 20147618 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0
Study 18217142 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggrenox
Number of subjects: 30
Study 18217142 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 81 mg
Number of subjects: 30
Study 16251213 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exposure to galantamine (single dose)
Number of subjects: 46
Study 16251213 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure to galantamine (5 days)
Number of subjects: 46
Study 14604244 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent prebypass heparin dosing (100 IU/kg, three consecutive doses with a 4 min interval)
Number of subjects: 20
Study 14604244 — intervention group
Group type: COMPARATOR
Intervention: Standard single prebypass heparin dose (300 IU/kg)
Number of subjects: 20
Study 10623914 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling Group 1
Number of subjects: 0
Study 10623914 — intervention group
Group type: COMPARATOR
Intervention: Counseling Group 2
Number of subjects: 0
Study 9186303 — intervention group
Group type: EXPERIMENTAL
Intervention: Mono diet (n = 12)
Number of subjects: 28
Study 9186303 — intervention group
Group type: COMPARATOR
Intervention: NCEP diet (n = 18)
Number of subjects: 28
Study 9186303 — intervention group
Group type: COMPARATOR
Intervention: Baseline diet (rich in fat and saturated fatty acids)
Number of subjects: 28
Study 9186303 — intervention group
Group type: EXPERIMENTAL
Intervention: M1M1 genotype
Number of subjects: 28
Study 1584620 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted optic nerve head analysis system
Number of subjects: 15
Study 3847391 — intervention group
Group type: EXPERIMENTAL
Intervention: New approach to preoperative teaching
Number of subjects: 0
Study 3847391 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard preoperative teaching)
Number of subjects: 0
Study 31070388 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-prevention interactive video intervention
Number of subjects: 540
Study 27704654 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS with saline-soaked sponges of different thicknesses
Number of subjects: 26
Study 27704654 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS with saline-soaked sponges of different thicknesses
Number of subjects: 26
Study 27704654 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin sponges
Number of subjects: 26
Study 27704654 — intervention group
Group type: EXPERIMENTAL
Intervention: Thick sponges
Number of subjects: 26
Study 25725625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 1.5 mg kg(‐1) day(‐1) for 28 days
Number of subjects: 23
Study 25725625 — intervention group
Group type: COMPARATOR
Intervention: Acute ephedrine (2.5 mg/kg) after 28 days of treatment
Number of subjects: 23
Study 23551710 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent influenza virus vaccine (TIV) in pregnant women
Number of subjects: 56
Study 23551710 — intervention group
Group type: COMPARATOR
Intervention: Trivalent influenza virus vaccine (TIV) in non-pregnant women
Number of subjects: 56
Study 21775166 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive targets for LDL-C, non-HDL-C and SBP
Number of subjects: 499
Study 21775166 — intervention group
Group type: COMPARATOR
Intervention: Standard targets for LDL-C, non-HDL-C and SBP
Number of subjects: 499
Study 21775166 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive and Standard targets
Number of subjects: 499
Study 19838086 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir/Lamivudine (ABC/3TC)
Number of subjects: 21
Study 19838086 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir/Emtricitabine (TDF/FTC)
Number of subjects: 21
Study 16821257 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 114
Study 15575809 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned lenses with carboxymethylcellulose (CMC)
Number of subjects: 61
Study 10770306 — intervention group
Group type: EXPERIMENTAL
Intervention: PBSC
Number of subjects: 39
Study 10770306 — intervention group
Group type: COMPARATOR
Intervention: Bone Marrow
Number of subjects: 39
Study 9293310 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic assisted vaginal hysterectomy
Number of subjects: 22
Study 9293310 — intervention group
Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 22
Study 8223838 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine 1 mg once daily
Number of subjects: 60
Study 8223838 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine 2 mg once daily
Number of subjects: 60
Study 8223838 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine 0.5 mg once daily
Number of subjects: 60
Study 8223838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2939197 — intervention group
Group type: EXPERIMENTAL
Intervention: HEVAC B vaccine
Number of subjects: 214
Study 2939197 — intervention group
Group type: EXPERIMENTAL
Intervention: GCC VAC vaccine
Number of subjects: 214
Study 2939197 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 214
Study 2939197 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship to index carrier
Number of subjects: 214
Study 30136707 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate nasal spray at 200 microgram once daily for 3 months
Number of subjects: 187
Study 30136707 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin tablet at 250 mg once daily for 3 months
Number of subjects: 187
Study 28697803 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity and nutrition program (intervention group)
Number of subjects: 363
Study 28697803 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 363
Study 25711157 — intervention group
Group type: EXPERIMENTAL
Intervention: Gyrus ACMI/Olympus Invisio DUR-D
Number of subjects: 101
Study 25711157 — intervention group
Group type: COMPARATOR
Intervention: Olympus URF-V
Number of subjects: 101
Study 24335582 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing 1 hour before dialysis
Number of subjects: 40
Study 24335582 — intervention group
Group type: COMPARATOR
Intervention: Testing during the first hour of dialysis
Number of subjects: 40
Study 24335582 — intervention group
Group type: EXPERIMENTAL
Intervention: Both testing periods
Number of subjects: 40
Study 20803028 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofeedback training
Number of subjects: 60
Study 20803028 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive muscular strength training
Number of subjects: 60
Study 20803028 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 20803028 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study 19155592 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 g D-psicose alone
Number of subjects: 20
Study 19155592 — intervention group
Group type: COMPARATOR
Intervention: 75 g maltodextrin alone
Number of subjects: 20
Study 19155592 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g maltodextrin + 2.5 g D-psicose
Number of subjects: 20
Study 19155592 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g maltodextrin + 5 g D-psicose
Number of subjects: 20
Study 19155592 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g maltodextrin + 7.5 g D-psicose
Number of subjects: 20
Study 16753648 — intervention group
Group type: EXPERIMENTAL
Intervention: Detoxification (DTX)
Number of subjects: 243
Study 16753648 — intervention group
Group type: COMPARATOR
Intervention: Not in treatment (NT)
Number of subjects: 243
Study 12663312 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened version of computer-based instruction (less than 1.5 hours)
Number of subjects: 117
Study 12663312 — intervention group
Group type: COMPARATOR
Intervention: Full version of computer-based instruction (2.5 hours)
Number of subjects: 117
Study 10506661 — intervention group
Group type: EXPERIMENTAL
Intervention: Random peptide libraries (RPLs) screening with IDDM sera
Number of subjects: 0
Study 10506661 — intervention group
Group type: EXPERIMENTAL
Intervention: CH1p mimotope
Number of subjects: 0
Study 10506661 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimentally raised anti-osteopontin antibodies
Number of subjects: 0
Study 10506661 — intervention group
Group type: EXPERIMENTAL
Intervention: cDNA library screening
Number of subjects: 0
Study 8932874 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI182780 6 mg/day (n = 10) for 7 days
Number of subjects: 43
Study 8932874 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (4 x 40 mg on day 1, 20 mg/day thereafter, median 21 days) (n = 8)
Number of subjects: 43
Study 8932874 — intervention group
Group type: COMPARATOR
Intervention: Control (no preoperative treatment n = 9, placebo n = 7)
Number of subjects: 43
Study 8932874 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI182780
Number of subjects: 43
Study 8932874 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 43
Study 8932874 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 43
Study 1992531 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin 60 mg/m2 with 67.2 Gy radiation
Number of subjects: 36
Study 1992531 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin 50 mg/m2 with 67.2 Gy radiation
Number of subjects: 36
Study 1992531 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (various doses) with 58.8 Gy radiation
Number of subjects: 36
Study 1992531 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (various doses) with radiation
Number of subjects: 36
Study 6342396 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial of labor
Number of subjects: 105
Study 6342396 — intervention group
Group type: COMPARATOR
Intervention: Elective cesarean section
Number of subjects: 105
Study 6342396 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial of labor and Elective cesarean section
Number of subjects: 105
Study 30811872 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (n = 133)
Number of subjects: 200
Study 30811872 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 67)
Number of subjects: 200
Study 30788944 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 m×5 shuttle runs at dominant side
Number of subjects: 10
Study 30788944 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 m×5 shuttle runs at non-dominant side
Number of subjects: 10
Study 30788944 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 m×10 shuttle runs at dominant side
Number of subjects: 10
Study 30788944 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 m×10 shuttle runs at non-dominant side
Number of subjects: 10
Study 30788944 — intervention group
Group type: EXPERIMENTAL
Intervention: All exercise loads
Number of subjects: 10
Study 30788944 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery period (20 minutes)
Number of subjects: 10
Study 27234480 — intervention group
Group type: EXPERIMENTAL
Intervention: eCMP (Electronic Cardio-Metabolic Program) for 6 months
Number of subjects: 74
Study 25107840 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine-induced killer (CIK) cell treatment
Number of subjects: 0
Study 25107840 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CIK treatment)
Number of subjects: 0
Study 22897472 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Environments (IVE) with manipulated ostracism
Number of subjects: 0
Study 22897472 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 20838741 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg once daily in ambulatory patients
Number of subjects: 1084
Study 20838741 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg once daily in non-ambulatory patients
Number of subjects: 1084
Study 20838741 — intervention group
Group type: COMPARATOR
Intervention: Placebo in ambulatory patients
Number of subjects: 1084
Study 20838741 — intervention group
Group type: COMPARATOR
Intervention: Placebo in non-ambulatory patients
Number of subjects: 1084
Study 20838741 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin vs. placebo in ambulatory patients
Number of subjects: 1084
Study 20838741 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin vs. placebo in non-ambulatory patients
Number of subjects: 1084
Study 20838741 — intervention group
Group type: EXPERIMENTAL
Intervention: History of VTE
Number of subjects: 1084
Study 20838741 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer
Number of subjects: 1084
Study 18269820 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI combined with tirofiban therapy (Tirofiban group, n = 80)
Number of subjects: 160
Study 15386821 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus pioglitazone (15 mg o.d. titrated up to 45 mg)
Number of subjects: 630
Study 15386821 — intervention group
Group type: COMPARATOR
Intervention: Metformin plus gliclazide (80 mg o.d. titrated up to 320 mg)
Number of subjects: 630
Study 11870502 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with sequential subcutaneous IL-2 and IFN-alpha
Number of subjects: 124
Study 11870502 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 124
Study 10354810 — intervention group
Group type: EXPERIMENTAL
Intervention: Active viewing task (aDF)
Number of subjects: 0